Osteoarthritis and Bone Disorders News

ORLANDO, Fla. — Templating, bone grafting and using a rim-fitting porous cup are effective for addressing primary or secondary acetabular protrusio, a rare problem that can occur in patients with rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteomalacia or Paget’s disease, as well as in post-traumatic situations.

The American Academy of Orthopaedic Surgeons Board of Directors approved new appropriate use criteria for management of osteoarthritis of the hip.

Patients with rheumatoid arthritis who take biologic disease-modifying antirheumatic drugs, including those with concurrent denosumab use, demonstrated a low occurrence of serious and opportunistic infections, according to a study published in the Journal of Rheumatology.

Physicians and other health professionals report multiple barriers impeding nonpharmacological and nonsurgical care for osteoarthritis, according to research published in the Journal of Clinical Rheumatology.

SAN DIEGO — The structural benefits of sprifermin, a novel recombinant human fibroblast growth factor 18, suggest it may be effective for the disease-modifying treatment of osteoarthritis, according to research presented at the American College of Rheumatology.

Among older adults, a lower 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D ratio, also known as the vitamin D metabolic ratio, is a stronger predictor of hip fracture risk than 25-(OH)D measurement alone, according to study data published in Bone.

In patients with osteoarthritis and meniscal tear, the presence or persistence of effusion-synovitis appears to be associated with progression of cartilage damage, according to data presented at the American College of Rheumatology Annual Meeting.

The FDA is investigating the drug Limbrel, a capsule-based product currently marketed as a medical food to manage the metabolic processes associated with osteoarthritis, for what the administration calls “serious adverse events.”

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Marc C. Hochberg, MD, spoke about a study that evaluated the efficacy and safety of intra-articular sprifermin in patients with symptomatic radiographic knee osteoarthritis. When sprifermin was administered at a higher dose at 6 months or 12 months it slowed progression of joint space loss or cartilage thinning and was associated with an increase in cartilage thickness.

In five countries during a 10-year period, there have been statistically significant increases in the lifetime risk for total hip replacement surgery for osteoarthritis, as well as significant differences between sexes, according to results presented at the American College of Rheumatology Annual Meeting in San Diego.